RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $409 from $430 and keeps an Outperform rating on the shares as part of a ...

RBC Capital lowered the firm’s price target on Hologic (HOLX) to $75 from $83 and keeps a Sector Perform rating on the shares as part of a ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...